AI assistant
Lupin Ltd — Capital/Financing Update 2020
Dec 28, 2020
61031_rns_2020-12-28_e9242726-665a-49fd-9608-250c67644f10.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [84 x 99] intentionally omitted <==
December 28, 2020
BSE Limited
Department of Corporate Services, P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.
Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dear Sir/Madam,
Enclosed is a Press Release as regards the launch by the Company of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the U.S. FDA.
This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Thanking you,
For LUPIN LIMITED
Rajvardhan
Vishnu Satam
Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, o=Personal, 2.5.4.20=e8a002ede68da3b7e41e01d21c2b9062761a29a5f00 491762a5ac549cb034cae, postalCode=400104, st=Maharashtra, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f 726cdb67a2ff09c4242771b2a, cn=Rajvardhan Vishnu Satam Date: 2020.12.28 13:59:00 +05'30'
R. V. SATAM COMPANY SECRETARY (ACS -11973)
Encl- : a/a.
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN
Lupin launches Meloxicam Capsules
Mumbai, Baltimore, December 28, 2020 : Lupin Limited (Lupin), global pharmaceutical company, announced today the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration.
Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex[®] Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc., and indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex®) had an annual sales of approximately USD 11 million in the U.S. (IQVIA MAT October 2020).
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3[rd] largest pharmaceutical company in the U.S. by prescriptions and 5[th] in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/ Facebook: www.facebook.com/LupinWorld/
For further information or queries, please contact –
Shweta Munjal Arvind Bothra Manjira Sharma Head – Corporate Communications Head – Investor Relations and M&A General Manager – Corporate Communications Email: [email protected] Email: [email protected] Email: [email protected]
*Safe Harbor Statement
Vivlodex® is a registered trademark of Zyla Life Sciences Corporation .
Page 1 of 1